PRODUCTS
ProfilActis
Indication: CANCER
Profilactis is a formulation of paclitaxel combined to exopolysaccharide.
ProfilActis increases immunogenicity (induces heat shock proteins, activates cytokines, chemokine, and co-stimulatory molecules in cancer cells, blocks TGF-beta production in cancer cells).
ProfilActis breaks tolerance to multiple antigens at once and attracts antigen presenting cells (APC) locally.
ProfilActis does not need steps of gamma-irradiation, transformation and expansion.
ProfilActis clinical development can be accelerated because of a track record of safety of paclitaxel.
Technical Targeted Health Claim
Anticancer vaccine
Survival of tumor-free C57BL/6 mice vaccinated on day 0 and 14 with Profilactis-pretreated B16 cells (105) or g-irradiated cells formulated or not with monophosphoryl lipid A (MPL) adjuvant, and challenged at day 21 with viable B16 cells (106).